Raymond James Financial Inc. bought a new stake in shares of Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 264,704 shares of the company's stock, valued at approximately $21,669,000. Raymond James Financial Inc. owned approximately 0.21% of Vaxcyte at the end of the most recent quarter.
Several other hedge funds and other institutional investors have also bought and sold shares of the stock. Whipplewood Advisors LLC acquired a new stake in shares of Vaxcyte during the fourth quarter worth $28,000. Smartleaf Asset Management LLC lifted its position in Vaxcyte by 188.4% during the 4th quarter. Smartleaf Asset Management LLC now owns 398 shares of the company's stock worth $33,000 after acquiring an additional 260 shares during the period. Meeder Asset Management Inc. grew its stake in Vaxcyte by 1,007.9% during the 3rd quarter. Meeder Asset Management Inc. now owns 698 shares of the company's stock valued at $80,000 after purchasing an additional 635 shares during the last quarter. Blue Trust Inc. increased its holdings in shares of Vaxcyte by 100.0% in the fourth quarter. Blue Trust Inc. now owns 742 shares of the company's stock valued at $61,000 after purchasing an additional 371 shares during the period. Finally, Assetmark Inc. raised its stake in shares of Vaxcyte by 77,500.0% in the fourth quarter. Assetmark Inc. now owns 776 shares of the company's stock worth $64,000 after purchasing an additional 775 shares during the last quarter. Institutional investors own 96.78% of the company's stock.
Insider Buying and Selling
In related news, COO Jim Wassil sold 8,000 shares of Vaxcyte stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $73.27, for a total transaction of $586,160.00. Following the sale, the chief operating officer now directly owns 154,931 shares in the company, valued at $11,351,794.37. This trade represents a 4.91 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Teri Loxam sold 6,250 shares of the firm's stock in a transaction dated Wednesday, January 15th. The stock was sold at an average price of $85.11, for a total value of $531,937.50. Following the transaction, the director now directly owns 7,175 shares in the company, valued at approximately $610,664.25. The trade was a 46.55 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 46,250 shares of company stock worth $3,840,018. Corporate insiders own 3.10% of the company's stock.
Analyst Upgrades and Downgrades
PCVX has been the subject of a number of recent research reports. The Goldman Sachs Group started coverage on Vaxcyte in a research note on Friday, December 20th. They set a "buy" rating and a $135.00 price objective for the company. Guggenheim reaffirmed a "buy" rating and set a $160.00 price objective on shares of Vaxcyte in a research note on Wednesday, March 12th. Finally, Needham & Company LLC reaffirmed a "buy" rating and issued a $140.00 price target on shares of Vaxcyte in a report on Wednesday, February 26th. Nine analysts have rated the stock with a buy rating, According to MarketBeat, the company has a consensus rating of "Buy" and an average target price of $147.50.
Read Our Latest Stock Report on Vaxcyte
Vaxcyte Trading Up 2.0 %
Vaxcyte stock traded up $1.46 during trading on Wednesday, hitting $76.18. The company had a trading volume of 736,941 shares, compared to its average volume of 927,948. The stock has a market cap of $9.81 billion, a price-to-earnings ratio of -16.56 and a beta of 1.02. Vaxcyte, Inc. has a 1-year low of $58.10 and a 1-year high of $121.06. The company's 50 day simple moving average is $81.77 and its 200-day simple moving average is $94.41.
Vaxcyte (NASDAQ:PCVX - Get Free Report) last issued its quarterly earnings results on Tuesday, February 25th. The company reported ($1.02) EPS for the quarter, beating the consensus estimate of ($1.16) by $0.14. As a group, analysts forecast that Vaxcyte, Inc. will post -4.21 earnings per share for the current fiscal year.
About Vaxcyte
(
Free Report)
Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.
Featured Articles
Before you consider Vaxcyte, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vaxcyte wasn't on the list.
While Vaxcyte currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
